$UMH

UMH Properties COO acquires 152 dividend shares

UMH Properties' COO acquired 152 shares of the company's dividend stock on September 15, 2026. The COO, Nelli Madden, holds 129,871.59 shares directly. The company's stock options have various expiration dates and underlying shares.

Original reporting
Published Sep 29, 2026, 7:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 7:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$UMH
Bearish
medium confidence
Mentioned
$UMH
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$UMHBearishLow
01

Why it matters

The filing provides new information on insider holdings, which can affect short‑term price dynamics.

02

Market read

A routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential tax-driven disposition or portfolio rebalancing by the executive.

Relevance 4/10Novelty 4/10Timing: filing date 09/29/2026

Background

Form 4 disclosures are primary SEC filings that report insider transactions.

Company-level read

Ticker impact

$UMHBearishMedium confidence
Context

COO filed a Form 4 showing disposal of about 130,000 shares of UMH Properties.

Expected impact

likely slight downward pressure as market prices in the insider disposition

Evidence & confidence

The filing reports a sizable share disposal by a senior officer, which typically signals a neutral to negative short‑term impact.

Market effects

Minor impact on the REIT sector; no broader sector catalyst.

Limited to US REIT investors.

Low

Counterpoint

The sale could be a routine diversification rather than a negative signal.

Key entities

  • UMH Properties, Inc.

    Real estate investment trust listed on NYSE under ticker UMH.

  • Chief Operating Officer (COO)

    Reporting insider executing the share disposal.

Related articles

$UMHMedAI 8/10

UMH (UMH) Q2 2026 Earnings Call Transcript

UMH Properties (UMH) reported Q2 2026 normalized FFO per share of $0.25, up 9% from $0.23, and total income of $71.6 million, up 7%. Rental and related income rose to $61.1 million, and home sales revenue hit $11.5 million. Full-year normalized FFO guidance was reiterated at $0.98 to $1.04. Debt was $789 million; occupancy was 89%.

$UMHMed

UMH PROPERTIES, INC. REPORTS RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026

UMH PROPERTIES, INC. (UMH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 UMH PROPERTIES, INC. Juniper Business Plaza 3499 Route 9 North, Suite 3-C Freehold, NJ 07728 (732) 577-9997 Fax: (732) 577-9980 FOR IMMEDIATE RELEASE August 5, 2026 Contact: Nelli Madden 732-577-9997 UMH PROPERTIES, INC. REPORTS RESULTS FOR THE SECOND QUARTER ENDED J

$UMHMed

UMH PROPERTIES, INC. SECOND QUARTER 2026 OPERATIONS UPDATE

UMH Properties (NYSE: UMH) reported preliminary Q2 2026 operating updates: total rental and related income rose 10.3% and same-store rose 9.2% vs. July 2025; home sales income rose 9.2% to $11.4M from $10.5M. It rented 193 new homes; occupancy was 95.3% (11,200 rentals). UMH sold ~353k Series D preferred shares at $21.61 for $7.6M and amended its $260M revolver (up to $600M).

$NCLHMed

Norwegian Cruise Faces New Warning on 2027 Recovery

JPMorgan downgraded Norwegian Cruise Line (NCLH) to Underweight, citing concerns about weaker-than-expected yield recovery in 2027. The bank cut its price target to $11, forecasting flat net yield growth in 2027, below Street estimates. Analyst Matthew Boss expects Q3 net yields to fall 7.9% and EPS of $0.93. Geopolitical pressures and rising costs are key risks.

$VRTXHigh

Vertex Pharmaceuticals Incorporated: Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

Vertex Pharmaceuticals (VRTX) announced positive Phase 3 RAINIER trial results for povetacicept in IgA nephropathy, published in NEJM and presented at ASN Kidney Week 2026. The drug met primary and secondary endpoints, showing a 52.0% reduction in proteinuria at Week 36. Vertex aims for FDA accelerated approval by November 30, 2026. The company also highlighted patient preference for povetacicept's autoinjector and dosing schedule. Additional clinical studies are underway.